Aller au contenu principal
xMedica

Rechercher

63 études correspondent à ces filtres. Affichage de 51 à 63 sur 63 études

Résultats de la recherche
Numéro d'enregistrementÉtudeStatutPhaseRecrutementSites / paysAnnée de débutDernière mise à jourActions
NCT04852887De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Contact Revendiqué

Centre le plus proche : Wichita, Kansas, United States — à 43 km · 832 centres au total · contact indiqué

En recrutementPhase 31 670objectif832 / 4202123 avr. 2026
NCT06880055Shield Post-Approval Study Protocol

The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC usi…

Contact Revendiqué

Centre le plus proche : Hutchinson, Kansas, United States — à 36 km · 69 centres au total

En recrutement3 375objectif69 / 120257 août 2026
NCT06319820A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

Contact Revendiqué

Centre le plus proche : Wichita, Kansas, United States — à 43 km · 193 centres au total

En recrutementPhase 3641objectif193 / 20202428 août 2026
NCT02523014Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the g…

Contact Revendiqué

Centre le plus proche : Kingman, Kansas, United States — à 28 km · 783 centres au total

En recrutementPhase 2124objectif783 / 120152 sept. 2026
NCT06122077Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).

Contact Revendiqué

Centre le plus proche : Wichita, Kansas, United States — à 43 km · 36 centres au total · contact indiqué

En recrutement20 000objectif36 / 120235 août 2025
NCT06567743Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.

Contact Revendiqué

Centre le plus proche : Wichita, Kansas, United States — à 43 km · 80 centres au total · contact indiqué

En recrutementPhase 2325objectif80 / 220243 sept. 2026
NCT07190300TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Contact Revendiqué

Centre le plus proche : Wichita, Kansas, United States — à 43 km · 31 centres au total · contact indiqué

En recrutementPhase 1 / Phase 2181objectif31 / 14202623 juin 2026
NCT07764978Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnos…

Contact Revendiqué

Centre le plus proche : Wichita, Kansas, United States — à 43 km · 124 centres au total

En recrutementPhase 3750objectif124 / 15202614 août 2026
NCT05491525Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC

Contact Revendiqué

Centre le plus proche : Wichita, Kansas, United States — à 43 km · 38 centres au total · contact indiqué

En recrutementPhase 2 / Phase 371objectif38 / 16202215 juin 2026
NCT07296484Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the…

Contact Revendiqué

Centre le plus proche : Wichita, Kansas, United States — à 43 km · 61 centres au total · contact indiqué

En recrutementPhase 21 500objectif61 / 120259 sept. 2026
NCT05862272A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyoma…

Contact Revendiqué

Centre le plus proche : Wichita, Kansas, United States — à 43 km · 120 centres au total

En recrutementPhase 31 000objectif120 / 120236 août 2025
NCT05336240PCOM2 - The Physician Communication Intervention, Version 2.0

Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases. Though a previous provider communication intervention, called PCOM, wa…

Contact Revendiqué

Centre le plus proche : Wichita, Kansas, United States — à 43 km · 2 centres au total · contact indiqué

En recrutementSans objet120objectif2 / 1202326 août 2024
NCT07546929HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes

Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to cel…

Contact Revendiqué

Centre le plus proche : El Dorado, Kansas, United States — à 85 km · 25 centres au total · contact indiqué

En recrutementPhase 2300objectif25 / 1202323 avr. 2026

Filtres

Effacer tous les filtres